Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ardelyx Inc

ARDX
Current price
5.27 USD 0 USD (0.00%)
Last closed 5.27 USD
ISIN US0396971071
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 248 220 544 USD
Yield for 12 month +1.74 %
1Y
3Y
5Y
10Y
15Y
ARDX
21.11.2021 - 28.11.2021

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Address: 400 Fifth Avenue, Waltham, MA, United States, 02451

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.78 USD

P/E ratio

Dividend Yield

Current Year

+124 456 000 USD

Last Year

+52 158 000 USD

Current Quarter

+98 241 000 USD

Last Quarter

+73 222 000 USD

Current Year

+106 661 000 USD

Last Year

+48 041 000 USD

Current Quarter

+82 513 000 USD

Last Quarter

+63 217 000 USD

Key Figures ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -62 151 000 USD
Operating Margin TTM 2.27 %
PE Ratio
Return On Assets TTM -12.18 %
PEG Ratio -0.08
Return On Equity TTM -41.54 %
Wall Street Target Price 10.78 USD
Revenue TTM 251 848 992 USD
Book Value 0.67 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 74.2 %
Dividend Yield
Gross Profit TTM 15 540 000 USD
Earnings per share -0.32 USD
Diluted Eps TTM -0.32 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin -28.82 %

Dividend Analytics ARDX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.0383
Price Sales TTM 4.9562
Enterprise Value EBITDA -27.3593
Price Book MRQ 8.5586

Financials ARDX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARDX

For 52 weeks

4.34 USD 10.13 USD
50 Day MA 5.74 USD
Shares Short Prior Month 24 055 791
200 Day MA 6.53 USD
Short Ratio 4.69
Shares Short 23 308 546
Short Percent 11.19 %